. Although health authorities have warned about the increased risk of bone fractures with canagliflozin treatment, no firm conclusion about whether this is an effect of this class of inhibitors has been announced.
Ascertaining the mechanisms of increased fracture risk is difficult because bone health is a complex bio logical entity. Patients receiving SGLT2 inhibitors often have comorbidities that affect bone health, such as postmenopausal osteopenia and/or osteoporosis, coexisting chronic kidney disease (CKD) and type 2 diabetes. Several mechanisms have been suggested to mediate the adverse effects of SGLT2 inhibitors on bone health. First, SGLT2 inhibitors promote weight loss, which correlates with a biomarker of bone resorption, β carboxyterminal telopeptide of collagen type 1, but weight loss only explains a small percentage (~3%) of the variance in bone resorption biomarkers 3 . Second, SGLT2 inhibitors can induce postural hypotension, which might increase the risk of falls 4 . Although it is plausi ble that falling could increase fracture risk, it is unlikely that this accounts for the loss in bone mineral density from treatment with canagliflozin. Finally, oestradiol levels decreased by 9.2% in women receiving canagli flozin (300 mg/day) 3 ; although reduced oestradiol levels might contribute to the loss of bone mineral density, a correlation between the two measurements in individ ual patients has not been established. In summary, the mechanisms underlying canagliflozin induced fractures have not been fully elucidated.
In a recent study in healthy volunteers, we identi fied endocrine changes induced by canagliflozin that might mediate its adverse effects on bone health 5 . Canagliflozin treatment (300 mg/day) increased aver age serum phosphorus levels (the peak increase of 6.1 mg/l occurred after 36 h treatment), which cor related with increased transtubular reabsorption of phosphate. This increased serum phosphorus is remi niscent of that seen in patients with CKD, although the increase is larger in CKD patients. Whereas increased serum phosphorus levels result from decreased glomer ular filtration in patients with CKD, SGLT2 inhibitors increase proximal tubular reabsorption of phosphate. Nevertheless, both SGLT2 inhibitors and CKD trig ger the fibroblast growth factor 23 (FGF23)−1,25 dihydroxyvitamin D (1,25(OH) 2 D)-parathyroid hormone (PTH) axis. Plasma FGF23 levels increased by ~20% within 24 h of canagliflozin treatment (Fig. 1) , which was followed by a 10% decrease in plasma 1,25(OH) 2 D levels and a 25% increase in plasma PTH levels. The decreased 1,25(OH) 2 D level was likely mediated by a FGF23induced decrease in the expres sion of the cytochrome CYP27B1. We hypothesize that lower levels of 1,25(OH) 2 D decrease gastrointestinal absorption of dietary calcium, which in turn promotes PTH secretion. Consistent with this hypothesis, we observed a decrease in 24 h urinary calcium excretion on day 4 and day 5 (reF. 5 ). The combination of decreased 1,25(OH) 2 D and increased PTH levels is expected to be detrimental for bone health and might contribute to the increased fracture risk associated with SGLT2 inhibitors. Of note, increased serum phosphorus levels have been observed for all drugs of the SGLT2 inhibitor class. Similarly, a 1944 study reported that phlorizin (a non selective inhibitor of SGLT family cotransporters) treatment promoted tubular reabsorption of phosphate, which the researchers postulated results from glucose transporters and phosphate transporters competing for "an element common to the two mechanisms. " (reF.
6
). Furthermore, it is now established that glucose and phosphate are both reabsorbed by Na + dependent cotransporters that compete for the Na + electrochemical gradient. Thus, triggering the FGF23-1,25(OH) 2 D-PTH axis is likely a mechanismbased class effect shared by all SGLT2 inhib itors. Nevertheless, the magnitude of this adverse effect might vary among different SGLT2 inhibitors owing to differences in selectivity (SGLT1 versus SGLT2) or in the efficacy of approved doses for different drugs.
In healthy volunteers, canagliflozin treatment induced only a transient increase in serum phos phorus, followed by induction of FGF23 and PTH, which together function to restore serum phosphorus to normal levels. Whereas FGF23 and 1,25(OH) 2 D also returned to baseline levels, PTH levels remained elevated at the end of the 5day study. By contrast, the average increase in serum phosphorus (~1.5 mg/l) was sustained for at least 26 weeks in canagliflozin treated patients with type 2 diabetes and was even greater (~3.5 mg/l) in those patients who had impaired renal function (average estimated glomerular filtration rate 39 ml/min/1.73 m 2 ). Just as the increase in serum phos phorus was sustained in patients with diabetes, we hypothesize that the canagliflozin induced changes in FGF23, 1,25(OH) 2 D and PTH might also be sustained in patients with diabetes. Additional studies are needed to assess the magnitude of changes in bone related hor mones in response to chronic therapy with SGLT2 inhib itors in patients with diabetes. However, these studies are technically challenging because the diurnal variation in the levels of serum phosphorus, FGF23, 1,25(OH) 2 D and PTH might mask the similar magnitude drug induced changes. Consequently, it is crucial that the timing of blood tests is strictly controlled to minimize the risk of diurnal variation hiding the effect of the drug.
Most patients receiving SGLT2 inhibitors do not experience fractures. Given the considerable variation between individuals in the magnitude of canagliflozin induced changes in serum phosphorus and bone related hormones, how can patients at greatest risk of develop ing fractures be identified? We suggest that patients with the largest changes in 1,25(OH) 2 D and/or PTH might be at greatest risk and that calcitriol treatment might be beneficial for patients in whom an SGLT2 inhibitor induces the greatest reduction in 1,25(OH) 2 D levels. However, additional research will be required to test these hypotheses. Time course of pharmacodynamic responses to canagliflozin treatment. In a randomized crossover trial of 25 healthy volunteers, individuals were randomly assigned to treatment groups (placebo or canagliflozin (300 mg/day), a SGLT2 inhibitor (SGLT2i)) for five days and were subsequently crossed over to the other treatment (for further details of the study design, see reF. 
